Helus Pharma corrects press release on TARA Mind partnership for Phase 3 MDD trial, reaffirming alignment with executive order on mental health. HLP003 targetsHelus Pharma corrects press release on TARA Mind partnership for Phase 3 MDD trial, reaffirming alignment with executive order on mental health. HLP003 targets

Helus Pharma Corrects TARA Mind Partnership Announcement, Reaffirms Veteran Outreach Focus

2026/05/01 21:05
2 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists, issued a correction to its April 28, 2026 press release regarding its partnership with TARA Mind. The correction removes references to Veterans Exploring Treatment Solutions from earlier paragraphs, though the company reaffirmed the collaboration’s alignment with a recent executive order aimed at advancing mental health treatments and clinical research participation.

The partnership is designed to support Phase 3 recruitment for Helus Pharma’s HLP003 program, which targets major depressive disorder, and to expand outreach in veteran communities. HLP003 is a proprietary novel serotonergic agonist (NSA) that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. The company is currently enrolling patients for Phase 3 clinical development of HLP003 as an adjunctive treatment for major depressive disorder.

Helus Pharma, the commercial operating name of Cybin Inc., was founded in 2019 and is committed to developing synthetic molecules that activate serotonin pathways to promote neuroplasticity. The company’s proprietary NSAs are intended to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. In addition to HLP003, Helus Pharma is developing HLP004, another proprietary NSA in Phase 2 clinical development for generalized anxiety disorder.

The correction follows the company’s earlier announcement and clarifies the scope of the partnership with TARA Mind. The original press release can be viewed at https://ibn.fm/re8HL. Helus Pharma continues to operate in Canada, the United States, the United Kingdom, and Ireland, and provides updates on its website at www.helus.com.

The company’s newsroom, available at https://ibn.fm/HELP, provides the latest updates on its programs and initiatives. Helus Pharma’s focus on serotonergic agonists aims to improve the treatment landscape for mental health conditions by offering durable improvements through neuroplasticity.

This correction highlights the importance of accurate communication in clinical-stage pharmaceutical companies, especially when partnerships involve sensitive populations such as veterans. The alignment with the executive order underscores the broader push to enhance mental health treatments and increase clinical research participation among underserved groups.

Blockchain Registration, Verification & Enhancement provided by NewsRamp™

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Helus Pharma Corrects TARA Mind Partnership Announcement, Reaffirms Veteran Outreach Focus.

The post Helus Pharma Corrects TARA Mind Partnership Announcement, Reaffirms Veteran Outreach Focus appeared first on citybuzz.

Market Opportunity
Taraxa Coin Logo
Taraxa Coin Price(TARA)
$0.00004677
$0.00004677$0.00004677
+3.70%
USD
Taraxa Coin (TARA) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.